Form 4: Mira Pharmaceuticals Director Acquires Stock Options
SEC Form 4
Director Denil Nanji Shekhat acquired nonqualified stock options in Mira Pharmaceuticals on March 25, 2024.
Summary
- On March 25, 2024, Denil Nanji Shekhat, a director of Mira Pharmaceuticals, acquired 50,000 nonqualified stock options with an exercise price of $1.16.
- 25,000 of these options vested immediately, and the remaining 25,000 will vest on March 25, 2025.
- Following the transaction, Shekhat beneficially owns 25,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants to a director, neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by potentially diluting equity if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Director acquired 50,000 nonqualified stock options; 25,000 options vested immediately. |
| 03/25/2025 | Date when the remaining 25,000 stock options will vest. |
| 03/25/2034 | Expiration date of the nonqualified stock options. |
| 03/27/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.